(Reuters) – A Chinese experimental coronavirus vaccine being developed through the Institute of Medical Biology of the Chinese Academy of Medical Sciences has been shown in an initial clinical trial, the researchers said.
In a phase 1 trial of 191 healthy participants over the age of 18 to 59, vaccination with the group’s experimental vaccine showed no serious adverse effects, its researchers said Tuesday in an article https://www. medrxiv. org/content/10. 1101/2020. 09Array27. 20189548v1 on the medRxiv prepress server prior to peer review.
The maximum non-unusual side effects reported through the trial participants were mild pain, mild fatigue and redness, itching and swelling at the injection site.
The candidate induced an immune response.
“All the knowledge received in this trial on the protection and immunogenicity of this inactivated vaccine and is encouraging for further studies on its effectiveness in the future,” the paper states.
China has inoculated burdens of thousands of essential personnel and other top-threatening equipment with other vaccines, even though clinical trials were not fully completed, raising protection considerations among experts.
China has at least 4 experimental vaccines in the latter stages of clinical trials.
(Reporting through Miyoung Kim; Editing by Robert Birsel)